Status:
COMPLETED
Treatment of SARS Caused by COVID-19 With Ruxolitinib
Lead Sponsor:
Grupo Cooperativo de Hemopatías Malignas
Conditions:
COVID-19
Severe Acute Respiratory Syndrome Coronavirus 2
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
In December 2019, a new virus emerged in Wuhan, China rapidly becoming a pandemic with registered cases above 800,000 around the world. The virus is now known as SARS-CoV2 calling its disease coronavi...
Eligibility Criteria
Inclusion
- Patients with diagnosed COVID-19 with confirmatory test
- Increase in work of breathing or presence of dyspnea
- Presence of lung changes associated with COVID pneumonia by chest imaging
- Informed consent
Exclusion
- Pregnancy or breastfeeding
- Thrombocytopenia below 20,000 cells/mm3
- Neutropenia below 500 cels/mm3
- Known and active infection of HIV, Hepatitis C, Hepatitis B, Herpes Zoster or Mycobacterium Tuberculosis
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2021
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT04334044
Start Date
September 1 2020
End Date
April 30 2021
Last Update
July 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Grupo Cooperativo de Hemopatías Malignas
Huixquilucan, State of Mexico, Mexico, 52763